Baber R et al. Therapy for menopausal symptoms during and after treatment for breast cancer: Safety considerations. Drug Saf 2005;28(12):1085-1100. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

De Ziegler D et al. Clinical use of aromatase inhibitors (AI) in premenopausal women. J Steroid Biochem Mol Biol 2005;95(1-5):121-7. Abstract

Duric VM et al. Patients’ preferences for adjuvant endocrine therapy in early breast cancer: What makes it worthwhile? Br J Cancer 2005;93(12):1319-23. Abstract

Eneman JD et al. Selecting adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 2004;18(14):1733-44. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Fountzilas G et al. Hellenic Cooperative Oncology Group. Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: Five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. Am J Clin Oncol 2004;27(1):57-67. Abstract

Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 2004;11(3):391-406. Abstract

Kaklamani VG, Gradishar WJ. Adjuvant therapy of breast cancer. Cancer Invest 2005;23(6):548-60. Abstract

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Martin M et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 43.

Parulekar WR et al; National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study — NCIC CTG MA5. J Clin Oncol 2005;23(25):6002-8. Abstract

Petrek JA et al. Incidence, time course and determinants of menstrual bleeding after breast cancer treatments: A prospective study. ASCO 2005;Abstract 538.

Pritchard K. Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women. Breast Cancer Res 2005;7(2):70-6. Abstract

Rody A et al. Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther 2005;5(4):591-604. Abstract

Segura C et al. The use of GnRH analogues in early and advanced breast carcinomas. Gynecol Obstet Fertil 2005;33(11):914-9. Abstract

Swain SM et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) docetaxel (T) arm of NSABP B-30: Preliminary results. Proc ASCO 2005;Abstract 537.

Thewes B et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005;6(8):581-8. Abstract